Source:http://linkedlifedata.com/resource/pubmed/id/15173001
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0000768,
umls-concept:C0017262,
umls-concept:C0025269,
umls-concept:C0027651,
umls-concept:C0035647,
umls-concept:C0039082,
umls-concept:C0185117,
umls-concept:C0205282,
umls-concept:C0233820,
umls-concept:C0521324,
umls-concept:C1979963,
umls-concept:C1999230,
umls-concept:C2003903,
umls-concept:C2911684
|
pubmed:issue |
11
|
pubmed:dateCreated |
2004-6-2
|
pubmed:abstractText |
Identifying the molecular basis for genotype-phenotype correlations in human diseases has direct implications for understanding the disease process and hence for the identification of potential therapeutic targets. To this end, we performed microarray expression analysis on benign (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs) tumors from patients with multiple endocrine neoplasia (MEN) type 2A or 2B, related syndromes that result from distinctive mutations in the RET receptor tyrosine kinase. Comparisons of MEN 2B and MEN 2A MTCs revealed that genes involved in the process of epithelial to mesenchymal transition, many associated with the tumor growth factor beta pathway, were up-regulated in MEN 2B MTCs. This MEN 2B MTC profile may explain the early onset of malignancy in MEN 2B compared with MEN 2A patients. Furthermore, chondromodulin-1, a known regulator of cartilage and bone growth, was expressed at high levels specifically in MEN 2B MTCs. Chondromodulin-1 mRNA and protein expression was localized to the malignant C cells, and its high expression was directly associated with the presence of skeletal abnormalities in MEN 2B patients. These findings provide molecular evidence that associate the previously unexplained skeletal abnormalities and early malignancy in MEN 2B compared with MEN 2A syndrome.
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/AG13730,
http://linkedlifedata.com/resource/pubmed/grant/K08 HD047396-01,
http://linkedlifedata.com/resource/pubmed/grant/L40 HD045452-01,
http://linkedlifedata.com/resource/pubmed/grant/L40 HD045452-02,
http://linkedlifedata.com/resource/pubmed/grant/T32CA09547-17
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
64
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3907-13
|
pubmed:dateRevised |
2010-9-29
|
pubmed:meshHeading |
pubmed-meshheading:15173001-Gene Expression Profiling,
pubmed-meshheading:15173001-Humans,
pubmed-meshheading:15173001-Intercellular Signaling Peptides and Proteins,
pubmed-meshheading:15173001-Membrane Proteins,
pubmed-meshheading:15173001-Multiple Endocrine Neoplasia Type 2b,
pubmed-meshheading:15173001-Musculoskeletal Abnormalities,
pubmed-meshheading:15173001-Neoplasm Invasiveness,
pubmed-meshheading:15173001-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:15173001-RNA, Messenger,
pubmed-meshheading:15173001-Reverse Transcriptase Polymerase Chain Reaction
|
pubmed:year |
2004
|
pubmed:articleTitle |
Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors.
|
pubmed:affiliation |
Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|